Yangtze River Pharma Secures NMPA Approval for Fazamorexant – Next-Generation DORA for Insomnia Treatment
Yangtze River Pharmaceutical Group (YRPG) announced that China’s National Medical Products Administration (NMPA) has granted...
Fineline Cube
Boehringer Ingelheim and Sino Biopharmaceutical Secure NMPA Conditional Approval for Hernexeos in First-Line HER2-Mutant NSCLC With 76% Response Rate
Boehringer Ingelheim (BI) and Sino Biopharmaceutical Ltd (HKG: 1177) jointly announced that Hernexeos (zongertinib) has...
Jenscare’s LuX-Valve Plus Demonstrates 97.8% Efficacy in Tricuspid Regurgitation Reduction in Global EU TRINITY Study 12-Month Follow-Up
Jenscare Scientific Co., Ltd (HKG: 9877), a structural heart disease device manufacturer, announced 12-month follow-up...
Bayzed Health Group Partners With MicroPort Subsidiaries to Establish Specialized Cardiovascular and Surgical Robot Centers Across Hospital Network
Bayzed Health Group (HKG: 2609) announced a strategic partnership with two subsidiaries of fellow Chinese...
Transcenta and Inhibrx Report 20% Response Rate for Ozekibart in Heavily Pretreated Colorectal Cancer, Following Recent FDA Filing for Chondrosarcoma
Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced...
Sino Medical Sciences Secures EU Label Update for HT Supreme Stent, Enabling One-Month Dual Antiplatelet Therapy
Sino Medical Sciences Technology Inc. (SHA: 688108) announced European Union regulatory approval for a label...
Mabwell Bioscience Secures Second NMPA Approval for Denosu Biosimilar, Expanding Indication to Bone Metastases and Multiple Myeloma
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced it has received a second indication approval...
Pfizer’s 25-Valent Pneumococcal Vaccine Candidate Shows Superior Serotype 3 Response in Phase II Infant Study
Pfizer Inc. (NYSE: PFE) announced positive readouts from a Phase II clinical study evaluating its...
Medtronic to Acquire SPR Therapeutics for $650 Million, Expanding Chronic Pain Management Portfolio
Medtronic plc (NYSE: MDT) announced its intent to acquire SPR Therapeutics, Inc., a privately held...
BeOne Medicines Launches “One Save Changes Everything” Global Cancer Care Initiative, Partnering With Soccer Legend Tim Howard
BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly known as BeiGene, Ltd., today...
Bristol-Myers Squibb Partners With Anthropic to Deploy Claude AI Across Enterprise, Signaling Strategic Shift to Agentic Workflows
Bristol-Myers Squibb Company (BMS, NYSE: BMY) announced a strategic agreement with artificial intelligence pioneer Anthropic...
CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
CBC Group, the Singapore-based healthcare private equity firm, and Global Healthcare Opportunities (GHO), the UK-headquartered...
Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
Sanofi SA (NASDAQ: SNY) announced today positive data from the global ElevAATe Phase II clinical...
Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
A federal jury in the U.S. District Court for the District of Massachusetts returned a...
Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
Novartis AG (NYSE: NVS) announced today new data from the PSMAddition Phase III clinical trial...
China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
The China Population Welfare Foundation, in partnership with Lilly (NYSE: LLY) China, unveiled this week...
Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets
Hybio Pharmaceutical Co., Ltd. (SHE: 300199) announced today a strategic partnership agreement with two undisclosed...
Shanghai ZJ Bio-Tech Secures International Approvals for Molecular Diagnostic Platforms in Netherlands and Mexico
Shanghai ZJ Bio-Tech Co., Ltd. (SHA: 688317), a leading Chinese molecular diagnostic reagent specialist, announced...
Bayer’s Asundexian Receives FDA Priority Review for Secondary Stroke Prevention Following Positive Phase III OCEANIC-STROKE Trial
Bayer AG (ETR: BAYN) announced today that the U.S. Food and Drug Administration (FDA) has...